The effect of a single oral dose (800 mg) of zileuton (A-64077), a specific 5-lipoxygenase inhibitor, on the early and late airway responses to inhaled allergen was studied in a randomised, double blind, placebo controlled, and crossover trial in nine subjects with atopic asthma. Leukotriene generation was also assessed in vivo by measuring urinary leukotriene (LT) E4 excretion, and ex vivo by measuring calcium ionophore stimulated whole blood LTB4 production. Zileuton almost completely inhibited ex vivo LTB4 production but reduced urinary excretion of LTE4 by only about half. There was a trend for the early asthmatic response to be less on the day of zileuton treatment, but this did not reach statistical significance (p = 0 08). The zileuton induced reduction in maximum fall in FEVy in the early asthmatic response was, however, significantly related to the reduction in urinary LTE4 excretion (r = 0 8), but not to the reduction in LTB4 generation ex vivo. There was no significant change in the allergen induced late asthmatic response, or in the increase in airway responsiveness to methacholine following antigen. The results provide some support for the hypothesis that the cysteinyl leukotrienes have a role in the allergen induced early asthmatic response. More complete in vivo inhibition of 5-lipoxygenase may be needed to produce a significant reduction in airway response to allergen challenge.
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The leukotrienes, products of the 5-lipoxygenase pathway of arachidonic acid metabolism, are thought to be important mediators in the pathogenesis of asthma because their biological activities produce changes that are similar to those seen in asthma.'-3 The cysteinyl leukotrienes, LTC4, LTD4, and LTE4, are potent bronchoconstrictor agents in normal and asthmatic subjects,' and LTE4 has been reported to increase airway hyperresponsiveness.7 LTB4 is a potent chemotactic agent for leucocytes,8 and may be important in mediating the inflammatory process in asthmatic airways. LTD4 can increase mucus production in human airway preparations9 and airway microvascular leakage in animals.'0 Several clinical studies with cysteinyl leukotriene antagonists in asthmatic subjects have shown a slight reduction in the early asthmatic response to inhaled allergen" " and in cold air induced bronchoconstriction." The compounds studied were relatively weak cysteinyl leukotriene antagonists, however, and they would in addition leave the effects of the dihydroxy acid LTB4 unopposed. An alternative approach is to inhibit the 5-lipoxygenase enzyme to reduce synthesis of all the leukotrienes. Several different classes of 5-lipoxygenase inhibitors have been found to be effective in animal models of asthma. 14-16 No significant reduction of allergen induced bronchoconstriction was, however, proposed by piriprost" or nafazatrom'8 in two clinical studies in man-but nafazatrom was found not to prevent ex vivo leukotriene production in man after oral dosing despite having 5-lipoxygenase inhibitory activity in vitro (the activity of piriprost in man was not studied).
After exposure to inhaled allergen there is an early and late bronchoconstrictor response in asthmatic subjects and an increase in airway responsiveness. Several mediators, including the leukotrienes, are generated during antigen challenge and may be important in mediating the airway responses. Zileuton, a hydroxamic acid 5-lipoxygenase inhibitor,'9 has been shown to inhibit calcium ionophore stimulated human neutrophil production of LTB4 in man ex vivo after oral dosing,'0 and is effective in inhibiting allergen induced contraction of tracheal smooth muscle in the guinea pig.2' We have investigated the efficacy of zileuton (800 mg) on the generation of cysteinyl leukotriene in vivo (assessed by urine LTE4 concentration) induced by inhaled allergen and on the generation of LTB4 ex vivo (by calcium ionophore stimulated whole blood) in asthmatic subjects. We assessed the inhaled allergen induced airway responses of the early and late asthmatic response and changes in airway responsiveness.
Methods

SUBJECTS
Eleven non-smoking men with atopic asthma (mean age 28, range years) with an FEV1 above 70% predicted were recruited (table). Subjects were having inhaled salbutamol only, apart from one who was also inhaling steroids and taking oral theophyllines. All subjects had been shown to have a dual asthmatic response to allergen on screening. None had had an upper respiratory tract infection or exacerbation of asthma within six weeks of starting the study. Nonsteroidal anti-inflammatory drugs were not allowed during the study period. The study was approved by the ethics committee of the National Heart and Lung Hospitals, and fully informed written consent was obtained from each subject.
Subjects had to be healthy at the physical examination and to have normal results in biochemical and haematological tests and a normal electrocardiogram before entry into the study. These were repeated during the study and at the end to assess the safety and tolerability of zileuton.
STUDY PROTOCOL
Allergen challenge On a screening day the atopy of each subject was confirmed by obtaining a positive skinprick test response to either Dermatophagoides pteronyssinus or mixed grass pollen allergen extracts (Pharmacia, Milton Keynes) dissolved in normal saline. Subjects first inhaled the diluent, aerosolised with a Wright nebuliser (volume 2 ml, flow rate 7 1/min, output 0-2 ml/min), through a face mask with open mouthed tidal breathing for two minutes, and FEV, was then measured for 15 minutes to exclude a bronchoconstrictor response to diluent. Cumulative doses of allergen were then inhaled in the same way to identify subjects with a dual asthmatic response. The initial allergen concentration used for inhalation was that which caused a 2-3 mm diameter weal in the skinprick test. Doubling concentrations of allergen were inhaled until an early asthmatic response (fall in FEV, of at least 20% of the post-diluent value) was seen.
No further allergen was then given, FEVy was measured up to eight hours to detect any late asthmatic response, which was defined as a fall in FEV, of at least 15% of post-diluent value.
If a dual response was seen, the final allergen dose reached was used on the two allergen challenge study days. Of the 17 subjects screened, six subjects with an isolated early asthmatic response were not enrolled into the main study.
Two to three weeks later subjects returned for the first allergen challenge study. Zileuton (800 mg) or matching placebo was ingested in the morning, and allergen challenge was per- tInhaled, apart from the theophylline (oral) taken by subject 9.
every 10 minutes for the first hour after challenge, and then hourly for the next seven hours. At least two weeks later subjects returned for the second study to continue with an identical protocol provided that the baseline FEV, was within 15% of that on the first study day. If not, they were asked to return for another study day.
FEV, was measured with a dry bellow spirometer (Vitalograph, Buckingham) with the subject sitting upright. The mean of three good expiratory efforts was taken. Before each test subjects rested in a warm room for at least 15 minutes. Non-specific airway responsiveness was assessed according to the method of Cockcroft et al2" on the day before and after each allergen test day, at the same time of the day for each subject. The provocative dose of methacholine needed to reduce FEV, by 20% of the post-diluent value (PC20 FEV,) was determined. Methacholine was inhaled in the same way as allergen.
Assessment of 5-lipoxygenase inhibition 5-Lipoxygenase activity after allergen challenge was assessed by measuring urinary LTE4 excretion. 23 Immediately before challenge subjects emptied their bladder and urine was then collected for four hours. Urine volume and pH were measured and aliquots of 30 ml were stored at -70°C. LTE4 was extracted from the urine by reverse phase high performance liquid chromatography, tritiated LTE4 being used as an internal standard,24 and measured by radioimmunoassay (Amersham International, Amersham). The efficacy of zileuton was also assessed by calcium ionophore stimulated whole blood LTB4 production ex vivo. Three and a half, four, five, seven, nine, and 10 hours after it was given 5 ml of whole blood was incubated with 5 to inhaled allergen, two were withdrawn. One developed an exacerbation of asthma following a chest infection after the first study day (placebo). The other subject who had an FEV, of just over 70% predicted was withdrawn when his FEV, fell to below 70% predicted before allergen challenge. The remaining nine subjects completed the study, and all results were included in the analysis. Zileuton was well tolerated and there were no important biochemical, haematological, or electrocardiographic changes after treatment. 
EFFECTS ON IN VIVO AND EX VIVO LEUKOTRIENE
GENERATION
Zileuton substantially inhibited calcium ionophore stimulated whole blood LTB4 production with maximum inhibition (931% of baseline; p < 0-005) four hours post-dose; after the dose had been given significant inhibition was still present at 10 hours after the dose (63-5% of baseline; p < 0-005; fig 3) . Mean urinary LTE4 excretion after allergen challenge was reduced by about half by zileuton treatment (placebo 111-5 (23 5), zileuton 58 2 (14 8) ng/mmol creatinine; p < 001; fig 4) .
The zileuton induced change in maximum fall in FEV, for the early asthmatic response correlated with the reduction in urinary LTE4 production (r = 0 8, p < 0 01; fig 5) but not with the inhibition of calcium ionophore stimulated whole blood LTB4 production (r = 0 04, p > 0 5).
PLASMA ZILEUTON CONCENTRATIONS
Mean plasma zileuton concentrations three and a half, four, and five hours after ingestion were 3-37 (0 36), 3 03 (0-39) and 2 6 (0-27) Mg/ml respectively on the days of zileuton treatment; no drug was detected on the placebo day. There was no relation between the peak drug concentrations and change in FEV, during the early and late asthmatic responses, reduction in urinary LTE4 excretion, or calcium ionophore stimulated whole blood LTB4 production.
Discussion
We found that zileuton at the dose used in the study partially reduced urinary LTE4 excretion and substantially reduced calcium ionophore stimulated whole blood LTB4 production ex vivo. There was a trend towards a reduction in the fall in FEV, during the early asthmatic response with zileuton, but neither this nor the late asthmatic response or increase in airway responsiveness differed significantly between zileuton and placebo. The change in the early asthmatic response induced by zileuton correlated with the change in urinary LTE4 concentrations but not with the change in ex vivo LTB4 production.
In vivo activation of the 5-lipoxygenase pathway in asthmatic patients during an asthmatic attack has been shown by the increased urinary excretion of LTE4,23 and by increased concentrations of cysteinyl leukotrienes in bronchoalveolar lavage fluid recovered by fibreoptic bronchoscopy during the early26 and late27 responses to inhaled allergen challenge. In the present study the activation of 5- , and are generated only after stimulation, so they would be expected to contribute more to the latter part of the early bronchoconstrictor response after allergen challenge. In a study by Britton and coworkers, in which a leukotriene antagonist, L649923, reduced the early response to allergen, the maximum effect was seen after the nadir of the early asthmatic response.'" In another study an antihistamine was effective in the first 15 minutes of the early asthmatic response after allergen challenge.0 The significant correlation between inhibition of in vivo LTE4 generation and reduction in early asthmatic response also supports the role of the leukotrienes as mediators in the early asthmatic response. Although the pattern of change in the early asthmatic response is similar to that in the study of Britton et al," the lack of statistical significance in our study may be due to a type II error.
Although leukotriene production has been shown during the late asthmatic response following allergen challenge,27 zileuton did not reduce the late fall in FEV, significantly in the present study. This may be because the activity of zileuton in the single dose of 800 mg used in this study may have been insufficient by that time, particularly when it was only partially effective during the early phase as measured by urinary LTE4 levels. In two patients where serum drug concentrations seven hours after the dose were available little zileuton was detected.
Previous studies of 5-lipoxygenase inhibitors in man have depended on ex vivo methods of assessing its activity. In the present study zileuton was more effective in inhibiting ex vivo calcium ionophore stimulated whole blood LTB4 production than in inhibiting leukotriene production in vivo as reflected by urinary LTE4 excretion, and there was no correlation between these two variables. There are several possible explanations. The lesser effect in vivo may be due to inadequate penetration of zileuton into airway tissues, or a higher plasma concentration may be needed to suppress airways 5-lipoxygenase adequately. Alternatively, different inflammatory cells may have different susceptibilities to the effect of zileuton, such that the mast cells, macrophages, or eosinophils in the airways may not have been affected as much as neutrophils in the peripheral blood. In addition, the cellular generation of the cysteinyl leukotrienes may be less affected than that of LTB,. The lack of relation between the changes in leukotriene generation ex vivo and the early asthmatic response suggest that this is not a useful method for assessing the clinical efficacy of 5-lipoxygenase inhibitors in man.
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